Related references
Note: Only part of the references are listed.Respiratory symptoms and lung function in patients treated for pulmonary tuberculosis in Malawi: a prospective cohort study
Rebecca Nightingale et al.
THORAX (2022)
High Rates of Recurrent Tuberculosis Disease: A Population-level Cohort Study
Sabine M. Hermans et al.
CLINICAL INFECTIOUS DISEASES (2021)
Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis
Avia Watson et al.
NATURE COMMUNICATIONS (2021)
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Synne Jenum et al.
NATURE COMMUNICATIONS (2021)
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Nikolaos C. Kyriakidis et al.
NPJ VACCINES (2021)
Vaccine Development Against Tuberculosis Over the Last 140 Years: Failure as Part of Success
Stefan H. E. Kaufmann
FRONTIERS IN MICROBIOLOGY (2021)
Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis
Stefanie Krug et al.
FRONTIERS IN IMMUNOLOGY (2021)
HOW COVID IS DERAILING THE FIGHT AGAINST HIV, TB AND MALARIA
Leslie Roberts
NATURE (2021)
Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations
Johan Vekemans et al.
VACCINE (2020)
Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis - End of the road?
Peter Mwaba et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
Giovanni Battista Migliori et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Clinical Development of New TB Vaccines: Recent Advances and Next Steps
Mark Hatherill et al.
FRONTIERS IN MICROBIOLOGY (2020)
WHO global progress report on tuberculosis elimination
Emilia Harding
LANCET RESPIRATORY MEDICINE (2020)
A natural polymorphism of Mycobacterium tuberculosis in the esxH gene disrupts immunodomination by the TB10.4-specific CD8 T cell response
Rujapak Sutiwisesak et al.
PLOS PATHOGENS (2020)
Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis
Sam Afkhami et al.
FRONTIERS IN IMMUNOLOGY (2020)
Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes
Wen-Ping Gong et al.
MILITARY MEDICAL RESEARCH (2020)
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations A Double-Blind, Placebo-controlled, Dose-Selection Trial
Sara Suliman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment
Margaretha de Vos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation
Sam Afkhami et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
D. R. Tait et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Moving tuberculosis vaccines from theory to practice
Peter Andersen et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
Rasmus Mortensen et al.
COMMUNICATIONS BIOLOGY (2019)
Prevention of M-tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
E. Nemes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
Stephane Leung-Theung-Long et al.
PLOS ONE (2018)
Antibodies and tuberculosis: finally coming of age?
Hao Li et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis
Hao Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial
Surendra K. Sharma et al.
SCIENTIFIC REPORTS (2017)
The Recombinant Bacille Calmette-Guerin Vaccine VPM1002: Ready for Clinical Efficacy Testing
Natalie E. Nieuwenhuizen et al.
FRONTIERS IN IMMUNOLOGY (2017)
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis A Randomized Trial
Richard N. van Zyl-Smit et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
A Functional Role for Antibodies in Tuberculosis
Lenette L. Lu et al.
CELL (2016)
Bacillus Calmette-Guerin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses
Sara Suliman et al.
JOURNAL OF IMMUNOLOGY (2016)
Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guerin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis
Martin Gengenbacher et al.
MICROBES AND INFECTION (2016)
The Progress of Therapeutic Vaccination with Regard to Tuberculosis
Pere-Joan Cardona
FRONTIERS IN MICROBIOLOGY (2016)
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine
Melissa Nyendak et al.
SCIENTIFIC REPORTS (2016)
Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study
Irene Andia Biraro et al.
BMC INFECTIOUS DISEASES (2015)
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
Angelique Kany Kany Luabeya et al.
VACCINE (2015)
Novel diagnostics and therapeutics for drug-resistant tuberculosis
Melody Toosky et al.
BRITISH MEDICAL BULLETIN (2014)
Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials
Punam Mangtani et al.
CLINICAL INFECTIOUS DISEASES (2014)
Aerosol Vaccination with AERAS-402 Elicits Robust Cellular Immune Responses in the Lungs of Rhesus Macaques but Fails To Protect against High-Dose Mycobacterium tuberculosis Challenge
Patricia A. Darrah et al.
JOURNAL OF IMMUNOLOGY (2014)
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo
David J. DiLillo et al.
NATURE MEDICINE (2014)
Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection
Andre S. Nell et al.
PLOS ONE (2014)
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults
Mark Hatherill et al.
VACCINE (2014)
Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment
Rhea N. Coler et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management
Vidyasagar Ramappa et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2013)
ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria
Diane Houben et al.
CELLULAR MICROBIOLOGY (2012)
Efficacy of Mycobacterium indicus pranii Immunotherapy as an Adjunct to Chemotherapy for Tuberculosis and Underlying Immune Responses in the Lung
Ankan Gupta et al.
PLOS ONE (2012)
Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis
Shaobin Shang et al.
VACCINE (2012)
A multistage tuberculosis vaccine that confers efficient protection before and after exposure
Claus Aagaard et al.
NATURE MEDICINE (2011)
Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine
Charles F. von Reyn et al.
AIDS (2010)
A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
Sylvie Bertholet et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®
C. Vilaplana et al.
VACCINE (2010)
Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis-infected Individuals
Clare R. Sander et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Foamy macrophages and the progression of the human tuberculosis granuloma
David G. Russell et al.
NATURE IMMUNOLOGY (2009)
Polyphasic Taxonomic Analysis Establishes Mycobacterium indicus pranii as a Distinct Species
Vikram Saini et al.
PLOS ONE (2009)
Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention
Ron P. Schuring et al.
VACCINE (2009)
Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis
Evelyn Guirado et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton
Elisabeth Rodriguez-Guell et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis
Sylvie Bertholet et al.
JOURNAL OF IMMUNOLOGY (2008)
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa
Tony Hawkridge et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
Katarina Radosevic et al.
INFECTION AND IMMUNITY (2007)
The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis
Sarah A. Stanley et al.
JOURNAL OF IMMUNOLOGY (2007)
Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis
Diana Dlugovitzky et al.
RESPIRATORY MEDICINE (2006)
Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice
Evelyn Guirado et al.
MICROBES AND INFECTION (2006)
Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection
P. J. Cardona et al.
ARCHIVOS DE BRONCONEUMOLOGIA (2006)
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
A Williams et al.
TUBERCULOSIS (2005)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
H McShane et al.
NATURE MEDICINE (2004)
Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis
J Stanford et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2004)
HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation
PA MacAry et al.
IMMUNITY (2004)
Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants
AM Vogel et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2002)
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
AS Pym et al.
MOLECULAR MICROBIOLOGY (2002)
Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis
JL Johnson et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
